MADISON, N.J.--(BUSINESS WIRE)--LEO Pharma Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Adbry ™ (tralokinumab-ldrm) for the treatment of moderate-to-severe atopic ...

MADISON, N.J.--(BUSINESS WIRE)--LEO Pharma A/S, a global leader in medical dermatology, today announced up to 3.5-year data that further support the long-term safety and efficacy profile of Adbry™ ...

The Adbry autoinjector is for use in adults only. A new single-dose autoinjector presentation of Adbry ® (tralokinumab-ldrm) is now available for use in the treatment of moderate to severe atopic ...

The approval was based on data from 3 pivotal phase 3 (ECZTRA 1-3) trials that evaluated the safety and efficacy of Adbry in 1934 adults with moderate to severe AD. The Food and Drug Administration ...

Leo Pharma has announced that its injection treatment for atopic dermatitis, Adbry (tralokinumab-ldrm), will gain an alternative mode of administration following a US Food and Drug Administration (FDA ...

Please provide your email address to receive an email when new articles are posted on . Full results of the long-term ECZTEND trial of Adbry for atopic dermatitis were announced at the Fall Clinical ...

Indication of Adbry (tralokinumab-ldrm) expanded to include patients 12 to 17 years of age with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical ...